Mitra Boolell

No ORCID on file · 4 papers in corpus · active 2023-2024

Study types

  • article 2
  • rct 1
  • review 1

Condition tags

  • dysmenorrhea 4
  • endometriosis 4
  • dyspareunia 3
  • chronic_pelvic_pain 1
review 2024
A review of the pharmacology, clinical outcomes, and real-world effectiveness, safety, and non-contraceptive effects of NOMAC/E2
European journal of obstetrics & gynecology and reproductive biology: X ·doi:10.1016/j.eurox.2024.100283

Selecting an appropriate oral contraceptive can be challenging for healthcare professionals due to the abundance of marketed contraceptive options with different clinical and real-world effectiveness and safety profiles. Nomegestrol acetate…

rct 2024
Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3)
Human Reproduction ·doi:10.1093/humrep/deae076

STUDY QUESTION: Does linzagolix administered orally once daily for up to 3 months at a dose of 75 mg alone or 200 mg in combination with add-back therapy (ABT) (1.0 mg estradiol; 0.5 mg norethindrone acetate, also known as norethisterone ac…

article 2024
O-269 Long term efficacy of Linzagolix in women with endometriosis-associated pain
·doi:10.1093/humrep/deae108.316

Abstract Study question Does once-daily linzagolix taken up to 12 months maintain pain reduction observed at 6 months in women with endometriosis? Summary answer Linzagolix alone or in combination with combined add-back therapy (ABT) for 12…

article 2023
O-027 Efficacy results from a phase 3, randomized, placebo-controlled trial testing two doses of linzagolix in women with endometriosis-associated pain
·doi:10.1093/humrep/dead093.027

Abstract Study question Does once-daily linzagolix for up to 6 months reduce the pain symptoms in women with endometriosis? Summary answer Once-daily oral use of the GnRH agonist linzagolix alone or in combination with combined hormonal add…